|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date08 May 1984 |
Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
杏芩感咳颗粒治疗感冒后咳嗽(风热伏肺证)的有效性和安全性随机对照剂量探索性Ⅱ期临床试验
[Translation] A randomized controlled dose-exploratory phase II clinical trial on the efficacy and safety of Xingqin Ganke granules in the treatment of cough after cold (wind-heat in the lungs syndrome)
以安慰剂为对照,初步评价杏芩感咳颗粒治疗感冒后咳嗽(风热伏肺证)的有效性和安全性,并进行剂量探索。
[Translation] Using placebo as a control, the efficacy and safety of Xingqin Ganke Granules in treating cough after cold (wind-heat in the lungs syndrome) were preliminarily evaluated, and a dose exploration was conducted.
100 Clinical Results associated with Shijiazhuang Dongfang Pharmaceutical Co. Ltd.
0 Patents (Medical) associated with Shijiazhuang Dongfang Pharmaceutical Co. Ltd.
100 Deals associated with Shijiazhuang Dongfang Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Shijiazhuang Dongfang Pharmaceutical Co. Ltd.